Company: NYXH
Filing Date: 2025-03-20
Form Type: F-3
Source: 0001104659-25-026217
Chunk: 62

Company: Nyxoah SA
Filing Date: 2025-03-20
Form: F-3
Chunk 62
---
 property of other organizations. Solely for convenience, trademarks and trade names referred to in this prospectus supplement appear without the ® and ™ symbols, but those references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or that the applicable owner will not assert its rights, to these trademarks and trade names.

<div align='center'>S-3</div>

TABLE OF CONTENTS

### THE OFFERING

#### Ordinary Shares offered by us
Ordinary shares having an aggregate offering price of up to $50.0 million, provided that the number of ordinary shares that may be sold in this offering may not exceed 5,662,694 shares.

#### Plan of Distribution
“At the market offering” that may be made from time to time through our sales agent, Cantor Fitzgerald & Co. See “Plan of Distribution” on page S-30of this prospectus supplement.

#### The Shares
Each ordinary share has a par value of €0.1718 per ordinary share.

#### Use of proceeds
We currently intend to use the net proceeds of this offering to (i) to advance the commercialization of the Genio system in our initial target markets outside of the United States and for pre-commercialization and commercialization activities in the United States; (ii) to continue gathering clinical data and to support physician initiated clinical research projects related to OSA patient treatments; (iii) to further finance research and development activities related to the next generation of the Genio system, re-designing our products for manufacturability and cost reduction initiatives, and to continue to build a pipeline of new technologies and explore potential collaboration opportunities in the field of monitoring and diagnostics for OSA; and (iv) for other general corporate purposes, including, but not limited to, working capital, capital expenditures, investments, acquisitions, should we choose to pursue any, and collaborations. See the section titled “Use of Proceeds” on page S-10of this prospectus supplement.

#### Risk factors
See “Risk Factors” beginning on page S-5of this prospectus supplement and the other information included in, or incorporated by reference into, this prospectus supplement for a discussion of certain factors you should carefully consider before deciding to invest in our ordinary shares.

#### Nasdaq Global Market Symbol
“NYXH”

The number of our ordinary shares to be outstanding immediately after this offering is 43,089,959 which is based on 37,427,265 ordinary shares outstanding as